Study of HYP-2090PTSA for KRAS-mutated advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new targeted pill called HYP-2090PTSA for people with advanced solid tumors that have a specific KRAS mutation. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of solid tumor that has spread or can't be removed by surgery, and your tumor has a specific genetic change called a KRAS mutation.
- You are at least 18 years old.
- You are able to do your usual daily activities without help (ECOG 0-1).
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are willing to use effective birth control during the study and for 6 months after the last dose.
- You have not had major surgery, cancer treatment, or a live vaccine in the last 4 weeks (or 2 weeks for some treatments).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
This trial tests a new drug, HYP-6589, alone for advanced solid tumors or combined with targeted therapy for advanced non-small cell lung cancer with specific gene changes. It aims to see if the treatment is safe and effective, and may help people whose cancer has spread or cannot be removed with surgery.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Hear when a new Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.